<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393379</url>
  </required_header>
  <id_info>
    <org_study_id>S445/2009</org_study_id>
    <nct_id>NCT01393379</nct_id>
  </id_info>
  <brief_title>ELVR in PH Patients With Severe Emphysema</brief_title>
  <official_title>Effect of Endoscopic Lung Volume Reduction (ELVR) on Pulmonary Hypertension (PH) in Patients With Severe Emphysema and Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of endoscopic valve implantation in&#xD;
      patients with COPD and PH on hemodynamics, symptoms, exercise tolerance and quality of life&#xD;
      in 10 patients in a prospective study. An improvement of objective parameters may also have a&#xD;
      prognostic significance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far there is no treatment of COPD in addition to the established treatment of concomitant&#xD;
      PH. Administration of PH-specific medication outside of clinical trials is not recommended in&#xD;
      new guidelines for PH of the ERS/ESC. The influence of endobronchial valve implantation on&#xD;
      the PH has not been studied in detail. The purpose of this study is to investigate the effect&#xD;
      of endoscopic valve implantation in patients with COPD and PH on hemodynamics, symptoms,&#xD;
      exercise tolerance and quality of life in 10 patients in a prospective study. An improvement&#xD;
      of objective parameters may also have a prognostic significance&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">10</enrollment>
  <condition>COPD</condition>
  <condition>Pulmonary Emphysema</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe emphysema and PH, where ELVR is indicated&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed patient consent form&#xD;
&#xD;
          -  men and women &gt;30 years&#xD;
&#xD;
          -  Clinically indicated endoscopic lung volume reduction&#xD;
&#xD;
          -  Pulmonary hypertension according to Group 3.1 of the Dana Point classification&#xD;
&#xD;
          -  Severe pulmonary emphysema&#xD;
&#xD;
          -  FEV1 &lt;45%&#xD;
&#xD;
          -  RV&gt; 150%&#xD;
&#xD;
          -  TLC&gt; 100%&#xD;
&#xD;
          -  Maximum of medical therapy according to GOLD&#xD;
&#xD;
          -  heterogeneous emphysema&#xD;
&#xD;
          -  Detected in the HR-CT&#xD;
&#xD;
          -  Confirmation of the heterogeneity of emphysema by computer-assisted quantification&#xD;
             (YACTA ®)&#xD;
&#xD;
          -  stable COPD&#xD;
&#xD;
          -  No exacerbation in the last 8 weeks&#xD;
&#xD;
          -  Cortisone dose &lt;20 mg prednisolone equivalent&#xD;
&#xD;
          -  Non-or ex-smoker&#xD;
&#xD;
          -  Nicotine abstinence&gt; 4 months&#xD;
&#xD;
          -  Actual CoHb &lt;2.5%&#xD;
&#xD;
          -  Diagnosis of pulmonary hypertension (PH), invasively diagnosed by right heart&#xD;
             catheterization:&#xD;
&#xD;
          -  Mean pulmonary arterial pressure (mPAP)&gt; 25 mmHg&#xD;
&#xD;
          -  Pulmonary capillary wedge pressure (PCWP) &lt;15 mmHg&#xD;
&#xD;
          -  Pulmonary vascular resistance (PVR)&gt; 320 dyne * sec * cm-5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PH of Group 1, 2, 4, 5 of the Dana Point Classification&#xD;
&#xD;
          -  Previous operations&#xD;
&#xD;
          -  s/p Lung resection (lobectomy / pneumonectomy)&#xD;
&#xD;
          -  s/p endoscopic lung volume resection&#xD;
&#xD;
          -  significant bronchiectasis&#xD;
&#xD;
          -  Sputum volume&gt; 4 tablespoons / day&#xD;
&#xD;
          -  Severe cardiac comorbidities:&#xD;
&#xD;
          -  s/p myocardial infarction in the last 6 weeks&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Cardiomyopathy with highly impaired LVF&#xD;
&#xD;
          -  Clopidogrel in long-term medication&#xD;
&#xD;
          -  Respiratory insufficiency: PaCO2 mmHg at rest&gt; 55&#xD;
&#xD;
          -  current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Corvinus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for pulmonary hypertension, Thoraxclinic Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for pulmonary Hypertension, Thoraxclinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Ekkehard Gruenig</investigator_full_name>
    <investigator_title>Prof. Grünig / PD Dr. Eberhardt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

